コンテンツへスキップ
Merck
  • Risk of colorectal cancer for people with a mutation in both a MUTYH and a DNA mismatch repair gene.

Risk of colorectal cancer for people with a mutation in both a MUTYH and a DNA mismatch repair gene.

Familial cancer (2015-07-24)
Aung Ko Win, Jeanette C Reece, Daniel D Buchanan, Mark Clendenning, Joanne P Young, Sean P Cleary, Hyeja Kim, Michelle Cotterchio, James G Dowty, Robert J MacInnis, Katherine M Tucker, Ingrid M Winship, Finlay A Macrae, Terrilea Burnett, Loïc Le Marchand, Graham Casey, Robert W Haile, Polly A Newcomb, Stephen N Thibodeau, Noralane M Lindor, John L Hopper, Steven Gallinger, Mark A Jenkins
要旨

The base excision repair protein, MUTYH, functionally interacts with the DNA mismatch repair (MMR) system. As genetic testing moves from testing one gene at a time, to gene panel and whole exome next generation sequencing approaches, understandin g the risk associated with co-existence of germline mutations in these genes will be important for clinical interpretation and management. From the Colon Cancer Family Registry, we identified 10 carriers who had both a MUTYH mutation (6 with c.1187G>A p.(Gly396Asp), 3 with c.821G>A p.(Arg274Gln), and 1 with c.536A>G p.(Tyr179Cys)) and a MMR gene mutation (3 in MLH1, 6 in MSH2, and 1 in PMS2), 375 carriers of a single (monoallelic) MUTYH mutation alone, and 469 carriers of a MMR gene mutation alone. Of the 10 carriers of both gene mutations, 8 were diagnosed with colorectal cancer. Using a weighted cohort analysis, we estimated that risk of colorectal cancer for carriers of both a MUTYH and a MMR gene mutation was substantially higher than that for carriers of a MUTYH mutation alone [hazard ratio (HR) 21.5, 95% confidence interval (CI) 9.19-50.1; p < 0.001], but not different from that for carriers of a MMR gene mutation alone (HR 1.94, 95% CI 0.63-5.99; p = 0.25). Within the limited power of this study, there was no evidence that a monoallelic MUTYH gene mutation confers additional risk of colorectal cancer for carriers of a MMR gene mutation alone. Our finding suggests MUTYH mutation testing in MMR gene mutation carriers is not clinically informative.